Introduction

pharmjournal

Разработка и регистрация лекарственных средств

Drug development & registration

2305-20662658-5049

LLC «CPHA»

10.33380/2305-2066-2022-11-4-95-107

pharmjournal-1363

Research Article

ФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ

PHARMACEUTICAL TECHNOLOGY

Impact of Parameter on Nanostructured Lipid Carrier Formulation and Approach of the Carrier for Cancer Treatment: a Brief Study

https://orcid.org/0000-0002-1822-7241

Sahoo

Laxmidhar Sahoo

Odisha, India

Laxmidhar Sahoo

Odisha, India

lsahoo81@gmail.com

https://orcid.org/0000-0002-0374-5433

Jena

G. K.

Jena

G. K.

Goutam Kumar Jena

Berhampur, Odisha, India

Goutam Kumar Jena

Berhampur, Odisha, India

https://orcid.org/0000-0003-2886-8664

Patro

C. S.

Patro

C. S.

Chandra Sekhar Patro

Bhubaneswar, Odisha, India

Chandra Sekhar Patro

Bhubaneswar, Odisha, India

Centurion University of Technology and ManagementCenturion University of Technology and Management

Roland Institute of pharmaceutical sciencesRoland Institute of pharmaceutical sciences

2022

25112022

11495107

2022

Sahoo L., Jena G.K., Patro C.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pharmjournal.ru/jour/article/view/1363

Introduction

Introduction. For the last decade, nanotechnology has been studied extensively in the pharmaceutical field. Among all the nanotechnology formulation areas, nanostructured lipid carrier is enormously researched by formulation scientists as it is one of the focused areas of lipid carrier for the effective formulation.

Materials and methods

Materials and methods. The nanostructured lipid carrier (NLC) consists of solid lipid, liquid lipid & surfactant for fabrication of formulation. Methods such as high energy methods, low energy methods and organic solvent-based methods are used for the preparation of NLC. As per literature study the High pressure homogenization is the most efficient method for fabrication of formulation.

Results and discussion

Results and discussion. This carrier system has significant advantages such as high drug entrapment, improved bioavailability, stability during storage, and targeting the site with a better-controlled release making it a prominent area for the formulator to emphasize on it. Although many drugs are formulated with a nanostructured lipid carrier, it is a concern for researchers to find out the effectiveness of formulation by studying the process parameter and safety.

Conclusion

Conclusion. The present review was focused to study the impact of various parameters such as Lipid, surfactant, homogenization rate, preservative, Crystallinity, and surface charge on the formulation. The study also extended towards toxicity and biocompatibility, topical targeting & cancer treatment of the Nanostructured lipid carrier.

Introduction

Materials and methods

Results and discussion

Conclusion

nanostructured lipid carriertoxicity & biocompatibilitysurface chargestabilitytopical targetingcancerbrain tumor target

References1

Khurana S., Jain N. K., Bedi P. M. Development of nanostructured lipid carriers for controlled delivery of mefenamic acid. Int J Biomed Nanosci Nanotechnol. 2012;2:232–50.

Mangesh B. R., Prashant U., Ashwini M. Solid Lipid Nanoparticles Incorporated Transdermal Patch for Improving the Permeation of Piroxicam. Asian Journal of Pharmaceutics. 2016;10(1).

Muller R. H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur. J. Pharm. Biopharm. 2000;50:161–177.

Dilip P., Dasgupta S., Dey S. et al. Nanostructured Lipid Carriers (NLC)-Based Gel for the Topical Delivery of Aceclofenac: Preparation, Characterization, and In Vivo Evaluation. Sci Pharm. 2012;80:749–764

Sharma A., Baldi A. Nanostructured Lipid Carriers: A Review. .J. Develop Drugs. 2018;7:191.

Patil D., Pattewar S., Palival S. et al. Nanostructured lipid carriers: a novel targeted drug delivery system. IJPSR. 2020;11(10):4784–4793.

Aldemar, Gordillo-Galeano, Elizabeth C., Mora-Huertas. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. European Journal of Pharmaceutics and Biopharmaceutics. 2018;133:285–308.

Noor N. M., Sheikh K., Somavarapu S., Taylor K. M. G. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery. Eur. J. Pharm. Biopharm. 2017;117:372–384. DOI: 10.1016/j.ejpb.2017.04.012.

Emami J., Rezazadeh M., Varshosaz J. et al. Formulation of LDL Targeted Nanostructured Lipid Carriers Loaded with Paclitaxel: A Detailed Study of Preparation, Freeze Drying Condition, and In Vitro Cytotoxicity. Journal of Nanomaterials. 2012;1–10. DOI: 10.1155/2012/358782.

Hu F. Q., Jiang S. P., Du Y. Z. et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids and Surfaces B. 2005;45(3–4):167–173.

Lin X., Li X., Zheng L. et al. Preparation and characterization of monocaprate nanostructured lipid carriers. Colloids and Surfaces A: Physicochem. Eng. Aspects. 2007;311:106–111. DOI: 10.1016/j.colsurfa.2007.06.003.

Anantachaisilp S., Smith S. M., Treetong A. et al. Chemical and structural investigation of lipid nanoparticles: drug–lipid interaction and molecular distribution. Nanotechnology. 2010;21(12):125102. DOI: 10.1088/0957-4484/21/12/125102.

Shimojo A. A. M., Fernandes A. R. V., Ferreira N. R. E., Sanchez-Lopez E., Santana M. H. A., Souto E. B. Evaluation of the Influence of Process Parameters on the Properties of Resveratrol-Loaded NLC Using 2<sup>2</sup> Full Factorial Design. Antioxidants. 2019;8(8):272. DOI: 10.3390/antiox8080272.

Ajiboye A. L., Nandi U., Galli M. Trivedi V. Olanzapine Loaded Nanostructured Lipid Carriers via High Shear Homogenization and Ultrasonication. Scientia Pharmaceutica. 2021;89(2):25. DOI: 10.3390/scipharm89020025.

Zirak M. B., Pezeshki A. Effect of Surfactant Concentration on the Particle Size, Stability and Potential Zeta of Beta carotene Nano Lipid Carrier. Int. J. Curr. Microbiol. App. Sci. 2015;4(9):924–932.

Gardouh A. R., Faheim S. H., Nouh A. T., Ghorab M. M. Influence of formulation factors on the size of nanostructured lipid Carriers and nanoemulsions prepared by high shear homogenization. Int J. Pharm Sci. 2018;10(4):61–75. DOI: 10.22159/ijpps.2018v10i4.23142.

Hernqvist L. Crystallization and Polymorphism of Fats and Fatty Acids. New York: Marcel Dekker; 1998. 97–137 p.

Sonoda T., Takata Y., Ueno S., Sato K. Effects of emulsifiers on crystallization behavior of lipid crystals in nanometer-size oil-in-water emulsion droplets. Cryst. Growth Des. 2006;(6):306–312. DOI: 10.1021/cg050045h.

Metin S., Hartel R. W. Crystallization of fats and oils. In: F. Shahidi, editor. Bailey’s Ind. Oil Fat Prod. 6 ed. New Jersey: John Wiley & Sons, Inc., Hoboken; 2005: 45–76 p. DOI: 10.1002/047167849X.bio021.

Mullin J. W. Crystallization. 4 ed. Oxford, UK: Butterworth-Heineman Ltd.; 2001. 172–260 p.

Chauhan I., Yasi M., Verma M., Singh A. P. Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery. Adv Pharm Bull. 2020;10(2):150–165.

Zhou L., Chen Y., Zhang Z., He J., Du M., Wu Q. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine. Pharmazie. 2012;67(4):304–310.

Teeranachaideekul V., Müller R. H., Junyaprasert V. B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-Effects of formulation parameters on physicochemical stability. Int. J. Pharm. 2007;340:198–206.

Khosa A., Reddi S., Saha R. N. Nanostructured lipid carriers for site-specific drug delivery. Biomedicine & Pharmacotherapy. 2018;103:598–613. DOI: 10.1016/j.biopha.2018.04.055.

Helgason T., Awad T. S., Kristbergsson K. et al. Impact of surfactant properties on oxidative stability of β-carotene encapsulated within solid lipid nanoparticles. J. Agric. Food Chem. 2009;57:8033–8040.

Obeidat W. M., Schwabe K., Müller R. H., Keck C. M. Preservation of nanostructured lipid carriers (NLC). European Journal of Pharmaceutics and Biopharmaceutics. 2010;76:56–67. DOI: 10.1016/j.ejpb.2010.05.001.

Uprit S., Sahu R. K., Roy A., Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharmaceutical Journal. 2013;21(4):379-85. DOI: 10.1016/j.jsps.2012.11.005.

Emami J., Yousefian H., Sadeghi H. Targeted nanostructured lipid carrier for brain delivery of artemisinin: Design, preparation, characterization, optimization and cell toxicity. J. Pharm. Sci. 2018;21:225s–241s.

How C. W., Rasedee A., Manickam S., Rosli R. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: Characterization, stability assessment and cytotoxicity. Colloids Surf. B Biointerfaces. 2013;112:393–399

Lu G. W., Gao P. Emulsions and Microemulsions for Topical and Transdermal Drug Delivery. In: Kulkarni V. S., editor. Handbook of Non-Invasive Drug Delivery Systems. 1st ed. UK: William Andrew; 2010.

Abdelbary G., Haider M. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of Methotrexate. Pharm. Dev. Technol. 2013;18:1159–1168

Muller R. H., Ruhl D., Runge S., Schulze-Forster K., Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997;14;458–462.

Almeida H., Lobao P., Frigerio C. et al. Preparation, characterization and biocompatibility studies of thermo responsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen. Pharm. Dev. Technol. 2017;22:336–349.

Bondi M. L., Craparo E. F., Giammona G. et al. Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv. 2007;14:61–67.

Vitorino C., Almeida J., Goncalves L. M. et al. Co-encapsulating nanostructured lipid carriers for transdermal application: from experimental design to the molecular detail. J. Control. Release. 2013;167:301–314.

Müller R. H., Radtke M., Wissing S. A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002;242:121–128. DOI: 10.1016/S0378-5173(02)00180-1.

Jenning V., Gohla S. H. Encapsulation of retinoids in solid lipid nanoparticles (SLN®). J. Microencapsul. 2001;18:149–158.

Czajkowska-Kosnik A., Szekalska M., Winnicka K. Nanostructured lipid carriers: A potential use for skin drug delivery systems. Pharmacological Reports. 2019;71:156–166.

Beloqui A., Solinıs M. A., Rodrıguez-Gascon A. et al. Nanostructured Lipid Carriers: promising drug delivery systems for future clinics. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(1):143–161.

Beloqui A. B., Solinis M. A., Rodriguez-Gascon A. et al. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomed – Nanotechnol. 2016;12:143–161.

Purohit D. K., Nandgude T. D., Poddar S. S. Nano-lipid carriers for topical application: current scenario. Asian J. Pharm. 2016;9(5):1–9.

Nakatuka Y., Yoshida H., Fukui K., Matuzawa M. The effect of particle size distribution on effective zeta-potential by use of the sedimentation method. Adv. Powder Technol. 2015;26:650–656.

Negi L. M., Talegaonkar S., Jaggi M. et al. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies. Colloids Surf. B. Biointerfaces. 2014;123:610–615.

Zhang W., Li X., Ye T., Chen F. et al Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int. J. Pharm. 2014;454(1):354–366.

Lin Y. K., Huang Z. R., Zhuo R. Z., Fang J. Y., Combination of calcipotriol and Methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomedicine. 2010;5:117–128.

Khajavinia A., Varshosaz J., Dehkordi A. J. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology. 2012;23(40):405101.

Han F., Li S., Yin R., Liu H., Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf. A. Physicochem. Eng. Asp. 2008;315:210–216.

O'Driscoll C. M., Griffin B. T. Biopharmaceutical challenges associated with drugs with low aqueous solubility the potential impact of lipid based formulations. Adv Drug Deliv Rev. 2008;60:617–624.

Kovacevic A., Savic S., Vuleta G., Muller R. H., Keck C. M. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int. J. Pharm. 2011;406(1–2):163–172.

Makeen H. A., Mohan S., Al-Kasim M. A. Sultan M. H., Albarraq A. A., Ahmed R. A., Alhazmi H. A., Alam M. I. Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib. Pharmaceutics. 2021;13:1086. DOI: 10.3390/pharmaceutics13071086.

Yu G., Ali Z., Khan A. S., Ullah K., Jamshaid H., Zeb A., Imran M., Sarwar S., Choi H.-G., ud Din F. Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers. Int. J. Nanomedicine. 2021;16:3255–3273. DOI: 10.2147/IJN.S299443.

Kim C. H., Kang T. H., Kim B. D., Lee T. H., Yoon H. Y., Goo Y. T., Choi Y. S., Kang M. J., Choi Y. W. Enhanced Docetaxel Delivery Using Sterically Stabilized RIPL Peptide-Conjugated Nanostructured Lipid Carriers: In Vitro and In Vivo Antitumor Efficacy Against SKOV3 Ovarian Cancer Cells. International Journal of Pharmaceutics. 2020;583:119393. DOI: 10.1016/j.ijpharm.2020.119393.

Poonia N., Narang J. K., Lather V., Beg S., Sharma T., Singh B., Pandita D. Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. Colloids Surf B Biointerfaces. 2019;181:756–766. DOI: 10.1016/j.colsurfb.2019.06.004.

Jiang H., Pei L., Liu N., Li J., Li Z., Zhang S. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy. Drug Delivery. 2016;23(4):1379–1382. DOI: 10.3109/10717544.2015.1048491.

Cao C., Wang Q., Liu Y. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Design, development and Therapy. 2019;13:1087–1098. DOI: 10.2147/dddt.s198003.

Akanda M., Getti G., Douroumis D. In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumors. Drug Delivery and Translational Research. 2021. DOI: 10.1007/s13346-021-01095-1.

Zhou J., Guo B., Zhu W., Sui X., Ma X., Qian J., Cao L., Han C. Novel biomimetic nanostructured lipid carriers for cancer therapy: preparation, characterization, and in vitro/in vivo evaluation. Pharmaceutical Development and Technology. 2020;26(1):81–91. DOI: 10.1080/10837450.2020.1835957.

Nordin N., Yeap S. K., Rahman H. S. et al. In vitro cytotoxicity and anticancer effects of citral nanostructured lipid carrier on MDA MBA-231 human breast cancer cells. Scientific report. 2019;9:1614.

Zhou L., Chen Y., Zhang Z., He J., Du M., Wu Q. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine. Pharmazie. 2012;67(4):304–310.

Neupane Y. R., Srivastava M., Ahmad N. et al. Lipid based nanocarrier system for the potential oral delivery of Decitabine: Formulation design, characterization, ex vivo, and in vivo assessment. Int. J. Pharm. 2014;477(1–2):601–612.

Zhang X. Y., Qiao H., Ni J. M., Shi Y. B., Qiang Y. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice. Eur. J. Pharm. Sci. 2013;49(3):411–422.

Qu C. Y., Zhou M., Chen Y. et al. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. Int. J. Nanomedicine. 2015;10:3911–3920.

Patel A. R., Chougule M. B., Ian T. et al. Efficacy of aerosolized Celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with Docetaxel. Pharm Res. 2013;30(5):1435–1446.

Wang Ya., Zhang H., Hao J. et al. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv. 2016;23(4):1398–1403.

Neupane Y. R., Srivastava M., Ahmad N. et al. Lipid based nanocarrier system for the potential oral delivery of Decitabine: Formulation design, characterization, ex-vivo, and in vivo assessment. Int. J. Pharm. 2014;477(1–2):601–612.

Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002;54(5):631–651.

Wang Z.-P., Wu J.-B., Chen T.-S. et al. In vitro and in vivo antitumor efficacy of berberine-nanostructured lipid carriers against H22 tumor. Biophotonics and Immune Responses X. 2015:(9324).

Khajavinia A., Varshosaz J., Dehkordi A. J. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology. 2012;23(40):405101.

Varshosaz J., Hassanzadeh F., Sadeghi H., Andalib S. Synthesis of octadecylamine-retinoic acid conjugate for enhanced cytotoxic effects of 5-FU using LDL targeted nanostructured lipid carriers. Eur. J. Med. Chem. 2012;54:429–438.

Khan A., Imam S. S., Aqil M., Ahad A., Sultana Y., Ali A., Khan K. Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses. Mol. Pharmaceutics. 2016;13:3773−3782.

Nandvikar N. Y., Lala R. R., Shinde A. S. Nanostructured lipid carrier: the advanced lipid carriers. IJPSR. 2019;10(12):5252–5265.

Zhang X., Pan W., Gan L. et al. Preparation of a Dispersible PEGylate Nanostructured Lipid Carriers (NLC) Loaded with 10-Hydroxycamptothecin by Spray-Drying. Chemical and pharmaceutical bulletin. 2008;56:1645–1650.

Sahoo L. Nanostructured lipid carrier (NLC)—a promising drug delivery for transdermal application. J. Pharm. Sci Res. 2020;12:475–487.

Devi D. R., Sandhya P., Hari B. N. V. Poloxamer: A Novel Functional Molecule For Drug Delivery And Gene Therapy. J. Pharm. Sci. & Res. 2013;5(8):159–165.

Garg J., Pathania K., Sah S. P., Pawar S. V. Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. Future Journal of Pharmaceutical Sciences. 2022;8:25.

Naseri N., Valizadeh H., Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure preparation and application. Adv. Pharm. Bull. 2015;5:305–313.

Das S., Chaudhury A. Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery. AAPS PharmSciTech. 2011;12:62–76.

Shirkhedkar A. A., Patil P. S. Breakthroughs in transdermal nanostructured lipid carrier drug delivery systems. IJPSR. 2021;12(3):1352–1366.

Shi L., Li Z., Yu L., Jia H., Zheng L. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. J Dispers Sci Technol. 2011;32(2):254–259.

Charcosset C., El-Harati A., Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release. 2005;108(1):112–120.

Thatipamula R. P., Palem C. R., Gannu R. Formulation and In vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. DARU. 2011;19(1):23–32.

Iqbal M. A., Md S., Sahni J. K., Baboota S., Dang S., Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J. Drug Target. 2012;20(10):813–830.

Trotta M., Debernardi F., Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm. 2003;257:153–160.

Sahoo L., Patro C. S., Jena G. K., Patro N., Satapathy S. A Focus on Fabrication, Characterization, Stability, Skin Targeting, Patent, Safety and Toxicity of Nanostructured Lipid Carrier. Journal of pharmaceutical research international. 2022;34(17B):49–76.

Haider M., Abdin S. M., Kamal L., Orive G. Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review. Pharmaceutics. 2020;12(3):288.

Rizwanullah M., Ahmad J., Amin S. Nanostructured Lipid Carriers: A Novel Platform for Chemotherapeutics. Current Drug Delivery. 2016;13(1):4–26.

Subramaniam B., Siddik Z. H., Nagoor N. H. Optimization of nanostructured lipid carriers: understanding the types, designs, and parameters in the process of formulations. J. Nanopart. Res. 2020;22:141.

Ranpise H. A., Gujar K. N., Pawar S. C., Awasthi R., Dua K., Mathure D., Madan J. R. Formulation, optimization, and evaluation of ketoconazole loaded nanostructured lipid carrier gel for topical delivery. Drug Deliv. Lett. 2020;10:61–71.

Kanojia N., Sharma N., Gupta N., Singh S. Applications of Nanostructured Lipid Carriers: Recent Advancements and Patent Review. Biointerface research in applied chemistry. 2022;12(1):638–652.

Ruktanonchai U., Bejrapha P., Sakulkhu U., Opanasopit P., Bunyapraphatsara N., Junyaprasert V., Puttipipatkhachorn S. Physicochemical Characteristics, Cytotoxicity, and Antioxidant Activity of Three Lipid Nanoparticulate Formulations of Alpha-lipoic Acid. AAPS PharmSciTech. 2009;10(1):227–234.

Fang M., Jin Y., Bao W., Gao H., Xu M., Wang D., Wang X., Yao P., Liu L. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int. J. Nanomedicine. 2012;7:5395–5404.

Hommoss A. Preservative system development for argan oil-loaded nanostructured lipid carriers. Pharmazie. 2011;66(3):187–191.

The authors declare that there are no conflicts of interest present.